Genomtec S.A. on April 13, 2026, at which the Shareholders will vote on an increase in the Company’s share capital through the issue of up to 2 million new series R shares and up to 204,000 series S shares, excluding pre-emptive rights.
Genomtec intends to use the funds raised from the new share issue primarily to support the M&A process and further implement key development projects. The funding will primarily cover testing the diagnostic parameters of the 3-plex variant of the Genomtec ID platform in the context of potential M&A transactions, as well as continuing projects that have already received grant funding. In this regard, the company plans to design and manufacture prototypes of reaction cards and the OncoSNAAT® analyzer for research purposes, as well as support a project utilizing AI solutions to develop primer sets for molecular diagnostics.
As part of the planned transaction, on March 17th of this year, the Company entered into an investment agreement with a significant shareholder, 5HT Family Foundation, under which the Shareholder agreed to conduct a public offering of up to 2 million existing shares, borrowed from Miron Tokarski, President of the Management Board of Genomtec, and Małgorzata Małodobra-Mazur, and to use all the proceeds to acquire newly issued Series R shares. Genomtec will thus obtain funds from the sale of Series R shares, which will be used to support the commercialization of projects as part of the M&A process conducted by Genomtec. Additionally, Genomtec obtained a PLN 1 million loan from shareholder 5HT Family Foundation with the right to convert the loan into shares.
„As part of the planned transaction, on March 17th of this year, the Company entered into an investment agreement with a significant shareholder, 5HT Family Foundation, under which the Shareholder agreed to conduct a public offering of up to 2 million existing shares, borrowed from Miron Tokarski, President of the Management Board of Genomtec, and Małgorzata Małodobra-Mazur, and to use all the proceeds to acquire newly issued Series R shares. Genomtec will thus obtain funds from the sale of Series R shares, which will be used to support the commercialization of projects as part of the M&A process conducted by Genomtec. Additionally, Genomtec obtained a PLN 1 million loan from shareholder 5HT Family Foundation with the right to convert the loan into shares”, says Miron Tokarski, President of the Management Board and co-founder of Genomtec SA.
The company’s flagship project is the Genomtec ID® mobile diagnostic system, which consists of an analyzer and a reaction card with integrated genetic tests. The Genomtec ID® platform is based on the proprietary SNAAT® solution and stands out from the competition for its mobility, speed, and ability to simultaneously diagnose multiple pathogens at the point of care. The OncoSNAAT® project, in turn, is a technology for detecting genetic changes occurring in cancer, which is crucial in personalized medicine, for example, when selecting targeted oncology treatments.
